COVID-19 Testing May Be Here to Stay, Suggests Study of 'Breakthrough' Cases
|
By LabMedica International staff writers Posted on 26 Apr 2021 |

Image: Teresa Rozza of Rockefeller’s Clinical Genomics Lab runs COVID saliva tests for the whole university community (Photo courtesy of Matthew Septimus)
A study of rare cases in which people who have been fully vaccinated against COVID and are immune to the virus can nevertheless develop the disease suggests that COVID testing may be here to stay.
New findings from The Rockefeller University (New York, NY, USA) suggest that these so-called breakthrough cases may be driven by rapid evolution of the virus, and that ongoing testing of immunized individuals will be important to help mitigate future outbreaks.
The research reports results from ongoing monitoring within the Rockefeller University community where two fully vaccinated individuals tested positive for the coronavirus. Both had received two doses of either the Moderna or the Pfizer vaccine, with the second dose occurring more than two weeks before the positive test. One person was initially asymptomatic and then developed typical COVID-19 symptoms; the other developed symptoms prior to testing. Both individuals recovered at home, an outcome consistent with evidence suggesting vaccination is effective in preventing severe disease.
Genome sequencing revealed multiple mutations in both viral samples, including the E484K variant in one individual, first identified in South Africa and Brazil, and the S477N variant in the other individual, which has been spreading in New York since November. The researchers were able to discern a quantifiable amount of virus in saliva samples from routine testing ongoing at Rockefeller, and sequence the viral RNA using a new coronavirus testing method. The observations suggest what is likely a small but ongoing risk among vaccinated individuals and the possibility that they may continue to spread the virus.
“These patients got vaccinated, had great immune responses, and nonetheless broke through with a clinical infection,” said Robert B. Darnell, The Robert and Harriet Heilbrunn Professor, who led the research. “The idea that we could be entirely done with testing in the post-vaccine world is probably not a good one right now; for example, even fully vaccinated people who develop respiratory symptoms should consider getting tested for COVID-19. Conversely, exposure to individuals with known infection, even if fully vaccinated, should be taken seriously and again individuals should consider getting tested.”
Related Links:
The Rockefeller University
New findings from The Rockefeller University (New York, NY, USA) suggest that these so-called breakthrough cases may be driven by rapid evolution of the virus, and that ongoing testing of immunized individuals will be important to help mitigate future outbreaks.
The research reports results from ongoing monitoring within the Rockefeller University community where two fully vaccinated individuals tested positive for the coronavirus. Both had received two doses of either the Moderna or the Pfizer vaccine, with the second dose occurring more than two weeks before the positive test. One person was initially asymptomatic and then developed typical COVID-19 symptoms; the other developed symptoms prior to testing. Both individuals recovered at home, an outcome consistent with evidence suggesting vaccination is effective in preventing severe disease.
Genome sequencing revealed multiple mutations in both viral samples, including the E484K variant in one individual, first identified in South Africa and Brazil, and the S477N variant in the other individual, which has been spreading in New York since November. The researchers were able to discern a quantifiable amount of virus in saliva samples from routine testing ongoing at Rockefeller, and sequence the viral RNA using a new coronavirus testing method. The observations suggest what is likely a small but ongoing risk among vaccinated individuals and the possibility that they may continue to spread the virus.
“These patients got vaccinated, had great immune responses, and nonetheless broke through with a clinical infection,” said Robert B. Darnell, The Robert and Harriet Heilbrunn Professor, who led the research. “The idea that we could be entirely done with testing in the post-vaccine world is probably not a good one right now; for example, even fully vaccinated people who develop respiratory symptoms should consider getting tested for COVID-19. Conversely, exposure to individuals with known infection, even if fully vaccinated, should be taken seriously and again individuals should consider getting tested.”
Related Links:
The Rockefeller University
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read more
Blood Test Detects More High-Risk Prostate Cancers Than PSA
Prostate cancer is one of the most common malignancies in men, and screening often struggles to distinguish indolent tumors from clinically significant disease. Prostate-specific antigen (PSA) testing... Read moreMolecular Diagnostics
view channel
Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read more
Genetic Marker Supports Anti-TNF Therapy Selection in Crohn’s Disease
Crohn’s disease, a major form of inflammatory bowel disease, is increasing across age groups and regions. Responses to current therapies vary widely, with only about half of patients benefiting, underscoring... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreMicrobiology
view channel
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Agreement Supports pTau217-Based Alzheimer’s Blood Test Development
As disease-modifying therapies for Alzheimer’s disease expand, accessible diagnostics are increasingly needed to identify patients earlier. Current confirmatory methods, including PET imaging and cerebrospinal... Read more









